GLP1R and early-onset autosomal dominant Alzheimer disease: For example, one of the GLP-1 receptor agonists, semaglutide, has been clinically studied for the reduction in neuroinflammation as well as amyloid-β and/or cortical tau protein in the brain with Alzheimer’s disease [78].